Posted by Michael Wonder on 01 Jul 2021
Neuroelectrics granted FDA breakthrough device designation for new therapeutic neuromodulation platform to treat refractory focal epilepsy
30 June 2021 - In a pilot study treating refractory epilepsy with Neuroelectrics’ Starstim platform, patients experienced a 44% median reduction in seizure frequency, with four patients experiencing a ≥75% reduction in seizure frequency.
Neuroelectrics has been granted FDA breakthrough device designation for its Starstim neuromodulation platform in refractory focal epilepsy.
